At All American Pharmaceutical, we don’t just formulate products—we prove them. That’s why we conducted this Karbolyn blood sugar study to understand how our patented carbohydrate performs in real metabolic conditions. What we found has implications not just for athletes, but for anyone concerned with a healthy glucose response.
A Placebo-Controlled Double-Blind Pilot Study: Blood Sugar Response by Normal, Pre-diabetic, and Type 2 Non-insulin Dependent Diabetic Volunteers to KarboLyn® or a Glucose Drink During Aerobic Activity
Jeff Golini, PhD., Wendy L. Jones, MS
All American Pharmaceutical, Billings, Montana; Royal Knight Incorporated, Rochester, Minnesota
Background
All American® Pharmaceutical originally developed KarboLyn® for carbohydrate loading. It was designed for elite athletes seeking a fast, safe, and high-performance way to easily load the muscle with readily available muscle glycogen. However, based on preliminary testing, KarboLyn® may have significant health and wellness properties important for treating the growing population of pre-diabetic and Type 2 diabetic conditions. While the mechanism remains unknown, similar studies using natural products, such as honey, suggest that the form of the sugar has a significant effect on glucose tolerance. KarboLyn® is a ‘designer sugar’ which appears to be processed differently than other carbohydrates.
Study Objectives
This clinical pilot study had three goals. (1) To document whether or not KarboLyn® had a positive and sustainable impact on blood sugar levels in normal individuals during light aerobic activity. (2) To observe the effect KarboLyn® had on pre-diabetic individuals, whether or not their glucose-resistant physiology would show the same controlled glucose utilization curve as that of normal individuals, with this product. (3) To observe whether non-insulin dependent diabetic blood glucose levels would renormalize, in the absence of diabetic medication, indicating that they may be processing KarboLyn® in a different manner than the placebo glucose drink.
Participants and Method
A total of 24 normal controls and 12 pre-diabetics were each given 50 grams of KarboLyn®, or a placebo glucose drink, for their trial. A total of 6 non-insulin-dependent Type 2 diabetics were withdrawn from their oral medication for 12 hours before being allowed to participate in the trial. Each diabetic volunteer was given 10 grams of KarboLyn® for their first trial and 10 grams of a placebo glucose drink one week later for their second trial. After consuming either KarboLyn® or a placebo, volunteers were asked to walk on a treadmill for 2 hours. Blood samples were taken every 15 minutes from all participants. The data is shown in the following graphs: (Detailed numbers can be seen by clicking the Research Poster Presentation image below)
Results
Preliminary evidence suggests that KarboLyn® can suppress sugar spikes and may lead to reductions in overall glucose levels in pre-diabetics and Type 2 diabetic responders. Follow-up studies are needed to generate additional evidence supporting the use of KarboLyn® as a potential glycemic stabilization product and for controlling long-term glucose levels in pre-diabetics and Type 2 diabetics.
Research Poster Presentation Image:
